Filing Details
- Accession Number:
- 0000950170-24-138134
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-12-18 20:52:52
- Reporting Period:
- 2024-12-16
- Accepted Time:
- 2024-12-18 20:52:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1744659 | Akero Therapeutics Inc. | AKRO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1779479 | Timothy Rolph | 601 Gateway Boulevard Suite 350 South San Francisco CA 94080 | Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-12-17 | 3,800 | $19.87 | 182,137 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-12-17 | 3,800 | $31.10 | 178,337 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-12-16 | 20,000 | $0.00 | 198,337 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-12-17 | 3,800 | $0.00 | 3,800 | $19.87 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2024-12-16 | 60,000 | $0.00 | 60,000 | $29.23 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 134,955 | 2033-12-08 | No | 4 | M | Direct | |
| 60,000 | 2034-12-15 | No | 4 | A | Direct |
Footnotes
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated August 12, 2024, previously adopted by the Reporting Person.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
- The options are vested and currently exercisable.
- This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 16, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Billionaire Hedge Funds
